NASDAQ:CARA - Cara Therapeutics Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $15.35 -0.04 (-0.26 %) (As of 01/21/2019 11:44 AM ET)Previous Close$15.39Today's Range$15.02 - $15.5052-Week Range$11.46 - $24.30Volume419,662 shsAverage Volume584,631 shsMarket Capitalization$603.11 millionP/E Ratio-8.25Dividend YieldN/ABeta2.95 ProfileDiscussionAnalyst RatingsChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Cara Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing chemical entities designed to alleviate pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body's peripheral nervous system and immune cells. Its lead product candidate includes KORSUVA (CR845/ difelikefalin) injection, which is in Phase III clinical trial for the treatment of patients with chronic kidney disease associated pruritus undergoing hemodialysis, as well as in Phase II/III clinical trial for the treatment of dialysis patients suffering from uremic pruritus. The company is also developing Oral KORSUVA (CR845/difelikefalin) that has completed Phase I clinical trial to treat uremic pruritus; and in Phase I clinical trial to treat pruritus chronic kidney disease, as well as in Phase I clinical trial for treating pruritus chronic liver disease. In addition, it is developing CR845/difelikefalin Injection, which is in Phase III clinical trial for the treatment of acute post-operative pain; and Oral CR845/difelikefalin that has completed Phase IIb for treating chronic pain, as well as CR701, which is in preclinical trial for the treatment of chronic pain. The company has license agreements with Maruishi Pharmaceutical Co., Ltd to develop, manufacture, and commercialize drug products containing CR845/difelikefalin for acute pain and uremic pruritus in Japan; and Chong Kun Dang Pharmaceutical Corporation to develop, manufacture, and commercialize drug products containing CR845/difelikefalin in South Korea. Cara Therapeutics, Inc. was founded in 2004 and is headquartered in Stamford, Connecticut. Receive CARA News and Ratings via Email Sign-up to receive the latest news and ratings for CARA and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:CARA Previous Symbol CUSIPN/A Webwww.caratherapeutics.com Phone203-406-3700Debt Debt-to-Equity RatioN/A Current Ratio4.89 Quick Ratio4.89Price-To-Earnings Trailing P/E Ratio-8.25 Forward P/E Ratio-7.17 P/E GrowthN/A Sales & Book Value Annual Sales$910,000.00 Price / Sales662.75 Cash FlowN/A Price / Cash FlowN/A Book Value$2.66 per share Price / Book5.77Profitability EPS (Most Recent Fiscal Year)($1.86) Net Income$-58,120,000.00 Net MarginsN/A Return on Equity-70.82% Return on Assets-50.95%Miscellaneous Employees37 Outstanding Shares39,290,000Market Cap$603.11 million OptionableOptionable Cara Therapeutics (NASDAQ:CARA) Frequently Asked Questions What is Cara Therapeutics' stock symbol? Cara Therapeutics trades on the NASDAQ under the ticker symbol "CARA." How were Cara Therapeutics' earnings last quarter? Cara Therapeutics Inc (NASDAQ:CARA) released its quarterly earnings results on Tuesday, November, 6th. The biopharmaceutical company reported ($0.51) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.46) by $0.05. The biopharmaceutical company earned $5.06 million during the quarter, compared to analyst estimates of $4.72 million. View Cara Therapeutics' Earnings History. When is Cara Therapeutics' next earnings date? Cara Therapeutics is scheduled to release their next quarterly earnings announcement on Thursday, March 21st 2019. View Earnings Estimates for Cara Therapeutics. What price target have analysts set for CARA? 11 equities research analysts have issued 1 year price objectives for Cara Therapeutics' shares. Their predictions range from $13.36 to $30.00. On average, they expect Cara Therapeutics' share price to reach $25.5360 in the next twelve months. This suggests a possible upside of 66.4% from the stock's current price. View Analyst Price Targets for Cara Therapeutics. What is the consensus analysts' recommendation for Cara Therapeutics? 11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cara Therapeutics in the last year. There are currently 1 hold rating and 10 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Cara Therapeutics. What are Wall Street analysts saying about Cara Therapeutics stock? Here are some recent quotes from research analysts about Cara Therapeutics stock: 1. According to Zacks Investment Research, "Cara Therapeutics, Inc. is a biopharmaceutical company. The company is focused on developing and commercializing new chemical entities designed to alleviate pain. Cara Therapeutics, Inc. is based in Shelton, United States. " (1/14/2019) 2. Cantor Fitzgerald analysts commented, "Compelling P2 safety and clinical activity data have been used to guide the design and risk-reduce pivotal P3 studies of IV KORSUVA in CKD-aP hemodialysis pts, from which we expect data in 2019. Our conviction for this program is bolstered by the significant partnership signed with a worldwide provider of hemodialysis services, which we believe validates the clinical and commercial potential. In addition, clinical success in CKD-aP could translate to other indications associated with pruritus, such as chronic liver disease, which should expand KORSUVA’s market opportunity." (10/4/2018) 3. HC Wainwright analysts commented, "We view this as a clear positive for the company, as it brings in minimally- dilutive financing ($50M cash plus $20M equity investment at $17/ share), validates our view on Korsuva, and de-risks the U.S. commercial launch. Despite the headline ex-US deal, we’re more focused on the new U.S. arrangement here because we don’t yet include ex-US in our model until we get more clarity on the regulatory and reimbursement landscape (our valuation is all-U.S.), and we assume the U.S. was also the primary value driver here for Vifor Fresenius as well. Vifor Fresenius is a JV of Vifor (VIFN:SW) and Fresenius Medical Care AG (FMS; not covered). We believe Vifor Fresenius is the best possible commercial partner for Cara, with Fresenius itself owning nearly 40% of U.S. dialysis centers." (5/23/2018) Has Cara Therapeutics been receiving favorable news coverage? Press coverage about CARA stock has trended positive recently, according to InfoTrie Sentiment Analysis. The research firm rates the sentiment of press coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Cara Therapeutics earned a news sentiment score of 2.7 on InfoTrie's scale. They also assigned media stories about the biopharmaceutical company a news buzz of 1.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the company's share price in the immediate future. Who are some of Cara Therapeutics' key competitors? Some companies that are related to Cara Therapeutics include Amicus Therapeutics (FOLD), Reata Pharmaceuticals (RETA), Endo International (ENDP), Arena Pharmaceuticals (ARNA), Opko Health (OPK), Mirati Therapeutics (MRTX), Heron Therapeutics (HRTX), Ironwood Pharmaceuticals (IRWD), Supernus Pharmaceuticals (SUPN), Innoviva (INVA), Endocyte (ECYT), AnaptysBio (ANAB), Xencor (XNCR), Insmed (INSM) and Madrigal Pharmaceuticals (MDGL). Who are Cara Therapeutics' key executives? Cara Therapeutics' management team includes the folowing people: Dr. Derek T. Chalmers, Co-Founder, Pres, CEO & Director (Age 55)Dr. Mani Mohindru, CFO & Chief Strategy Officer (Age 47)Dr. Joseph Stauffer, Consultant (Age 53)Dr. Michael E. Lewis, Co-Founder & Chief Scientific Advisor (Age 67)Mr. Scott M. Terrillion, Chief Compliance Officer, Gen. Counsel & Corp. Sec. (Age 56) Who are Cara Therapeutics' major shareholders? Cara Therapeutics' stock is owned by a variety of of institutional and retail investors. Top institutional investors include Virtu Financial LLC (0.05%). Company insiders that own Cara Therapeutics stock include Dean Slagel, Derek T Chalmers, Frederique PhD Menzaghi, Joseph William Stauffer, Mani Mohindru, Scott Terrillion and Ventures Vi Lp Rho. View Institutional Ownership Trends for Cara Therapeutics. Which major investors are buying Cara Therapeutics stock? CARA stock was purchased by a variety of institutional investors in the last quarter, including Virtu Financial LLC. View Insider Buying and Selling for Cara Therapeutics. How do I buy shares of Cara Therapeutics? Shares of CARA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Cara Therapeutics' stock price today? One share of CARA stock can currently be purchased for approximately $15.35. How big of a company is Cara Therapeutics? Cara Therapeutics has a market capitalization of $603.11 million and generates $910,000.00 in revenue each year. The biopharmaceutical company earns $-58,120,000.00 in net income (profit) each year or ($1.86) on an earnings per share basis. Cara Therapeutics employs 37 workers across the globe. What is Cara Therapeutics' official website? The official website for Cara Therapeutics is http://www.caratherapeutics.com. How can I contact Cara Therapeutics? Cara Therapeutics' mailing address is 107 ELM STREET 9TH FLOOR, STAMFORD CT, 06902. The biopharmaceutical company can be reached via phone at 203-406-3700. MarketBeat Community Rating for Cara Therapeutics (NASDAQ CARA)Community Ranking: 3.3 out of 5 ( )Outperform Votes: 512 (Vote Outperform)Underperform Votes: 265 (Vote Underperform)Total Votes: 777MarketBeat's community ratings are surveys of what our community members think about Cara Therapeutics and other stocks. Vote "Outperform" if you believe CARA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CARA will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 1/21/2019 by MarketBeat.com StaffFeatured Article: What is the downside to momentum investing?